Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
microRNA 552 (miR-552)
- Target
- miR-552
- Molecular classification
- microRNA, Small non-coding RNA, Post-transcriptional regulator
01
Overview
microRNA 552 (miR-552) is a small, non-coding RNA located on chromosome 1p34.3, functioning as a post-transcriptional regulator by binding to the 3′ untranslated region (UTR) of target mRNAs. It is upregulated in multiple cancers, promoting cell cycle progression, proliferation, migration, and invasion, while influencing apoptotic and ferroptosis pathways. miR-552 targets key genes such as TP53, RUNX3, ACSL4, and components of the Wnt/β-catenin pathway, driving tumorigenesis, drug resistance, and metastasis. Its expression profile and regulatory functions make it both a potential diagnostic/prognostic biomarker and a candidate therapeutic target, particularly in gastrointestinal and hepatic malignancies[1][2][3][5].
- Other names
- MIR552hsa-mir-552MIRN552miR-552-5p
02
Mechanism of action
Drugs targeting miR-552 typically act by inhibiting its expression or function (antagomiRs), restoring tumor suppressor gene activity, or modulating downstream pathways affected by miR-552 regulation (e.g., interfering with Wnt/β-catenin signaling or ACSL4-mediated ferroptosis).
03
Biological functions
Regulation of gene transcription and translationCell cycle progression and control (especially G1/S transition)Cell proliferationPromotion/inhibition of apoptosisRegulation of cell migration and invasionModulation of signaling pathways (notably Wnt/β-catenin signaling and ferroptosis regulation via ACSL4)EMT (epithelial-mesenchymal transition) regulation
04
Disease associations
Cancer (Colorectal cancer, Hepatocellular carcinoma, Gastric cancer, Lung cancer, Ovarian cancer, Ampulla adenocarcinoma, Osteosarcoma, etc.)Drug resistance in cancerTumor progression and metastasisFerroptosis modulation (in hepatocellular carcinoma)
05
Safety considerations
Therapeutic targeting of miR-552 could result in off-target effects due to its regulatory roles in multiple genes and pathways.Possible adverse effects if normal regulatory processes (e.g., cell cycle or apoptosis in non-cancer cells) are unintentionally disrupted.
06
Interacting drugs
No direct drugs targeting miR-552 have been approved; however, miR-552 affects the efficacy of anticancer agents such as 5-fluorouracil (5-FU) by mediating resistance. Research into miRNA mimics, inhibitors (antagomiR-552), and gene therapy approaches directed at miR-552 is ongoing.
07
Biomarkers
miR-552 itself may serve as a biomarker for diagnosis, prognosis, and drug resistance in cancers such as colorectal and liver cancer due to its elevated expression in tumors.
Beyond the preview
Go deeper on microRNA 552 (miR-552).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on microRNA 552 (miR-552).